Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes
Open Access
- 14 November 2012
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 35 (12), 2626-2630
- https://doi.org/10.2337/dc12-0270
Abstract
OBJECTIVE: In vivo, after subcutaneous injection, insulin glargine (21A-Gly-31B-Arg-32B-Arg-human insulin) is enzymatically processed into 21A-Gly-human insulin (metabolite 1 [M1]). 21A-Gly-des-30B-Thr-human insulin (metabolite 2 [M2]) is also found. In vitro, glargine exhibits slightly higher affinity, whereas M1 and M2 exhibit lower affinity for IGF-1 receptor, as well as mitogenic properties, versus human insulin. The aim of the study was to quantitate plasma concentrations of glargine, M1, and M2 after subcutaneous injection of glargine in male type 1 diabetic subjects. RESEARCH DESIGN AND METHODS: Glargine, M1, and M2 were determined in blood samples obtained from 12, 11, and 11 type 1 diabetic subjects who received single subcutaneous doses of 0.3, 0.6, or 1.2 units · kg−1 glargine in a euglycemic clamp study. Glargine, M1, and M2 were extracted using immunoaffinity columns and quantified by a specific liquid chromatography-tandem mass spectrometry assay. Lower limit of quantification was 0.2 ng · mL−1 (33 pmol · L−1) per analyte. RESULTS: Plasma M1 concentration increased with increasing dose; geometric mean (percent coefficient of variation) M1-area under the curve between time of dosing and 30 h after dosing (AUC0–30h) was 1,261 (66), 2,867 (35), and 4,693 (22) pmol · h · L−1 at doses of 0.3, 0.6, and 1.2 units · kg−1, respectively, and correlated with metabolic effect assessed as pharmacodynamics-AUC0–30h of the glucose infusion rate following glargine administration (r = 0.74; P < 0.01). Glargine and M2 were detectable in only one-third of subjects and at a few time points. CONCLUSIONS: After subcutaneous injection of glargine in male subjects with type 1 diabetes, exposure to glargine is marginal, if any, even at supratherapeutic doses. Glargine is rapidly and nearly completely processed to M1 (21A-Gly-human insulin), which mediates the metabolic effect of injected glargine.Keywords
This publication has 25 references indexed in Scilit:
- Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic SubjectsDiabetes Care, 2011
- Adventures with Insulin in the Islets of LangerhansJournal of Biological Chemistry, 2011
- In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its MetabolitesPLOS ONE, 2010
- Synchronization in G0/G1 enhances the mitogenic response of cells overexpressing the human insulin receptor A isoform to insulinCell Biology and Toxicology, 2009
- Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort studyDiabetologia, 2009
- Growth effects of insulin and insulin analoguesArchives of Physiology and Biochemistry, 2009
- Glargine blood biotransformation: in vitro appraisal with human insulin immunoassayDiabetes & Metabolism, 2007
- Pharmacokinetics and Pharmacodynamics of the Long-Acting Insulin Analog Glargine After 1 Week of Use Compared With Its First Administration in Subjects With Type 1 DiabetesDiabetes Care, 2007
- Qualitative Determination of Synthetic Analogues of Insulin in Human Plasma by Immunoaffinity Purification and Liquid Chromatography−Tandem Mass Spectrometry for Doping Control PurposesAnalytical Chemistry, 2005
- Evaluation of the Carcinogenic Potential of Insulin Glargine (LANTUS) in Rats and MiceInternational Journal of Toxicology, 2002